Up-regulation of the oncogenes myc and mycn is associated with poor outcomes of several cancers, such as aggressive neuroblastoma [63], large B cell lymphoma [64], acute myeloid leukemia (AML) [65] and nephroblastoma (Wilms tumor) [66]. Here, MYCN is linked to acute myeloid leukemia.